BMJ Rapid Recommendations: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists for type 2 diabetes

Published by Qiukui Hao on May 11, 2021

View

Disclaimer

Sponsors

Contact

Abstract

Language

en

PICOS

PICO 10.1

Population
Adults with type 2 diabetes plus 3 or fewer risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 10.2

Population
Adults with type 2 diabetes plus 3 or fewer risk factors and no underlying CVD or CKD
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 20.1

Population
Adults with type 2 diabetes plus 3 more risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 20.2

Population
Adults with type 2 diabetes plus 3 more risk factors and no underlying CVD or CKD
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 30.1

Population
Adults with type 2 diabetes and established CVD (but no CKD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 30.2

Population
Adults with type 2 diabetes and established CVD (but no CKD)
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 40.1

Population
Adults with type 2 diabetes and chronic kidney disease (but no CVD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 40.2

Population
Adults with type 2 diabetes and chronic kidney disease (but no CVD)
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 50.1

Population
Adults with type 2 diabetes and CVD and CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Standard care
Outcomes

PICO 50.2

Population
Adults with type 2 diabetes and CVD and CKD
Intervention
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Comparator
Standard care
Outcomes

PICO 60.1

Population
Adults with type 2 diabetes with 3 or fewer risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 60.2

Population
Adults with type 2 diabetes with 3 or more risk factors and no underlying CVD or CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 60.3

Population
Adults with type 2 diabetes with established CVD (but no CKD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 60.4

Population
Adults with type 2 diabetes and chronic kidney disease (but no CVD)
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes

PICO 60.5

Population
Adults with type 2 diabetes and CVD and CKD
Intervention
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Comparator
Glucagon-Like Peptide-1 (GLP-1) receptor agonists
Outcomes